Salute e Benessere

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR…

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platformsNovel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April25, 2025(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases,...
Nasdaq GlobeNewswire
25/04/2025

T-knife Therapeutics Presents Preclinical Data at the American Association for…

– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME TCR-T approaches, providing the potential for broad, deep and durable responses in hard-to-treat solid tumor indications– Submission of a Clinical Trial Application (CTA) for TK-6302 planned for the fourth quarter of 2025 and will be supported by a comprehensive body of data on its potency and safety SAN FRANCISCO and BERLIN,...
Nasdaq GlobeNewswire
25/04/2025

Press release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 25 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below…
Nasdaq GlobeNewswire
25/04/2025

2024 Annual Report Vistin Pharma ASA

Please find attached the Annual Report for 2024 for Vistin Pharma ASA (VISTN). There are no material changes in the financial statements compared to the preliminary full year results presented on 13 February 2025.The annual report for 2024 will also be made available onwww.vistin.com.***** For further information, please contact: Alexander Karlsen CFO +47 97 05 36 [email protected] This information is subject to the disclosure requirements pursuant to section...
Nasdaq GlobeNewswire
25/04/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 25 April 2025 at 17.20 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 24 April 2025...
Nasdaq GlobeNewswire
25/04/2025

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

The CHMP positive opinion is backed by a comprehensive clinical program comprising seven clinical studies, including two Phase 3 studies. The ACROINNOVA 1 study demonstrated that treatment with Oczyesa results in a significantly higher proportion of patients achieving normalized insulin growth-factor-1 (IGF-1) levels compared to placebo. The persistence of mean IGF-1 values and reduction of symptoms were confirmed over 52 weeks in the ACROINNOVA 2 study. Furthermore, the study showed…
PR Newswire
25/04/2025

Global Virtual Care Market to Surge: From $7.9 Billion in 2023 to $24.1 Billion…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-13A1900/Global_Virtual_Care_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-13A1900/Global_Virtual_Care_Market Major Factors Driving the Growth of Virtual Care Market: The virtual-care market is expanding rapidly because it solves three converging pressures on global health systems: soaring chronic-disease prevalence, chronic clinician shortages, and rising cost...
PR Newswire
25/04/2025

TUMI RELEASES LIMITED-EDITION 50TH ANNIVERSARY GOLD COLLECTION

"We wanted to do something truly special for our 50th anniversary," says Creative Director Victor Sanz. "And what better way to celebrate than by taking our iconic 19 Degree design and giving it a bold, metallic gold twist? This ultra-limited-edition drop is all about celebrating where we've been—50 years of pushing boundaries in design and craftsmanship—and where we're headed. It's the perfect blend of innovation, style and celebration." "We wanted to do something truly…
PR Newswire
25/04/2025

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line…

® ) as the first-line treatment for unresectable or metastatic melanoma has been approved by the National Medical Products Administration (“NMPA”). This marks the approval of toripalimab's 12th indication in the Chinese mainland.Melanoma is the most malignant type of skin cancer. According to GLOBOCAN 2022 statistics, approximately 332,000 new melanoma cases and 59,000 deaths were recorded globally that year. Though melanoma is relatively uncommon in China, its mortality rate is high...
Nasdaq GlobeNewswire
25/04/2025

Yatsen CEO on Science-Backed Beauty, Turnaround Strategy, and Global Positioning

A Vision to Build a Tech-Driven Beauty Powerhouse A Vision to Build a Tech-Driven Beauty Powerhouse Founded in 2016, Yatsen first captured attention through Perfect Diary, now a mainstream brand inChina. Since then, the company has expanded to 11 brands, spanning mass, masstige, and premium tiers. Its lineup includesFrance'sGalenic, focused on cellular anti-aging, the sensorial British skincare brandEVE LOM, and dermatologist-backed Dr.Wu. Together, these brands reflect a...
PR Newswire
25/04/2025

Samsonite's sustainability mission reaches new heights with innovative circular…

Samsonite is pushing the boundaries even further by launching two new circular luggage limited editions, which also carry a Digital Product Passport – a true breakthrough in enhancing transparency across the product lifecycle and providing access to key details about how we've incorporated more sustainable solutions, materials origin, and regulatory compliance. Samsonite is pushing the boundaries even further by launching two new circular luggage limited editions, which also carry a Digital...
PR Newswire
25/04/2025

Philips provides update on the Annual General Meeting of Shareholders 2025…

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) provides an update on the Annual General Meeting 2025 which has been convened on March 24, 2025 (AGM). As previously announced, the AGM agenda includes the proposal to appoint Mr Bob White (American, 1962) as a new member of the Supervisory Board, with effect from May 8, 2025, given his extensive expertise and experience in health technology and quality. Since the company published the agenda for the AGM, Mr White has...
Nasdaq GlobeNewswire
25/04/2025

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical…

CDH17 (Cadherin-17), a member of the cadherin superfamily, is an emerging therapeutic target in gastrointestinal cancers. Studies indicate that CDH17 is highly expressed in multiple gastrointestinal cancers including colorectal cancer, gastric cancer, pancreatic cancer, esophageal cancer, and plays a critical role in tumor invasion and metastasis. CDH17 (Cadherin-17), a member of the cadherin superfamily, is an emerging therapeutic target in gastrointestinal cancers. Studies indicate that…
PR Newswire
25/04/2025

Midea becomes Global Supporter of the AFC's club competitions

Datuk Seri Windsor John, the AFC General Secretary, said: "We are delighted to welcome Midea as a Global Supporter onboard this exciting journey, which further underlines the global appeal of the AFC's world-class club competitions, and are excited to work closely with them to create more unforgettable moments for our passionate Asian football fanbase." Datuk Seri Windsor John, the AFC General Secretary, said: "We are delighted to welcome Midea as a Global Supporter onboard this…
PR Newswire
25/04/2025

COSRX and YesStyle Conclude Record-Breaking Euro Supporters Recruitment, 100…

Designed to connect with the Gen Z beauty community across the continent, this groundbreaking collaboration between COSRX and YesStyle marked a first for both brands, spotlighting Korean skincare innovations through a new, interactive content marketing experience. The program received over 2,500 applications, demonstrating exceptional enthusiasm from beauty lovers in the UK, Germany, Italy, Spain, and France. Designed to connect with the Gen Z beauty community across the continent, this...
PR Newswire
25/04/2025

Notice of Annual General Meeting of Implantica AG

Anyone wishing to attend the annual general meeting must: Anyone wishing to attend the annual general meeting must: When giving notification to attend, please specify the SDR holder's name, personal identity or company registration number, address, telephone number and the number of any representative (no more than two). If SDR holders are represented by a proxy, a written and dated power of attorney signed by the SDR holder must be issued to the proxy. The power of attorney must not be...
PR Newswire
25/04/2025

Orion and Criceto Announce a License Agreement for APORON®, an Innovative…

ORION CORPORATIONPRESS RELEASE25 APRIL 2025 at 9.00 EEST Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson's Disease Orion Corporation (“Orion”) and Criceto IKM B.V. (“Criceto”) today announced the signing of an exclusive license agreement for the development and commercialization of APORON®, a novel apomorphine oromucosal spray for the treatment of OFF episodes in patients with...
Nasdaq GlobeNewswire
25/04/2025

Announcement of Paper Publication: EditForce Demonstrates Efficacy of Treatment…

The results of this study open the way for the development of treatments for the Disease, which currently has no fundamental cure, and are evaluated as demonstrating the innovativeness and efficacy of EditForce's proprietary PPR platform technology. It will continue to strive in its R&D activities to deliver the treatment for the Disease to patients as quickly as possible. The results of this study open the way for the development of treatments for the Disease, which currently has no...
PR Newswire
25/04/2025

Vistin Pharma ASA: First quarter 2025 financial results

thof April 2025Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2025.Revenue in the first quarter ended at MNOK 115 compared to MNOK 104 in Q1 2024. Sales volume in the quarter was up by 14% compared to same quarter last year.First quarter EBITDA ended at MNOK 30 compared to MNOK 20 in Q1 2024, an increase of 48%. EBITDA positively affected by increased sales volume and product mix in the quarter, in addition to continues focus on cost...
Nasdaq GlobeNewswire
25/04/2025

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic coughRepositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recoveryRegained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement...
Nasdaq GlobeNewswire
25/04/2025

New England Journal of Medicine publishes phase III data showing…

Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the influenza virus, from an infected person to household members by 32% 1 CENTERSTONE is the first global phase III trial that demonstrates the benefit of an antiviral in reducing the spread of a respiratory virus 1 Reducing the spread of infection within households could help limit transmission within institutions and communities, potentially easing the burden of...
Nasdaq GlobeNewswire
25/04/2025

Sobi and Sanofi's Foundation S extend partnership with the World Federation of…

The new signing comes as Sobi and Sanofi celebrate the tenth anniversary of answering the WFH call to action to support the global inherited bleeding disorders community through the donation of treatment products and financial aid. Between 2014 and 2024, Sanofi and Sobi provided one billion IUs of treatment product, enabling the treatment of 22,219 people with inherited bleeding disorders. The new signing comes as Sobi and Sanofi celebrate the tenth anniversary of answering the WFH call to...
PR Newswire
25/04/2025

Sanofi and Sobi extend their partnership with the World Federation of Hemophilia…

The new signing comes as Sanofi and Sobi celebrate the tenth anniversary of answering the WFH call to action to support the global inherited bleeding disorders community through the donation of treatment products and financial aid. Between 2014 and 2024, Sanofi and Sobi provided one billion IUs of treatment product, enabling the treatment of 22,219 people with inherited bleeding disorders. The new signing comes as Sanofi and Sobi celebrate the tenth anniversary of answering the WFH call to...
PR Newswire
25/04/2025

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical…

CDH17 (Cadherin-17), a member of the cadherin superfamily, is an emerging therapeutic target in gastrointestinal cancers. Studies indicate that CDH17 is highly expressed in multiple gastrointestinal cancers including colorectal cancer, gastric cancer, pancreatic cancer, esophageal cancer, and plays a critical role in tumor invasion and metastasis. CDH17 (Cadherin-17), a member of the cadherin superfamily, is an emerging therapeutic target in gastrointestinal cancers. Studies indicate that…
PR Newswire
25/04/2025
Altri  Comunicati